FDA tags Bay­er's prostate can­cer drug for pri­or­i­ty re­view as drug­mak­er gears up against ri­vals

Two months af­ter Bay­er and its Finnish part­ner Ori­on re­port­ed pos­i­tive late-stage da­ta for its prostate can­cer drug daro­lu­tamide, the Ger­man drug­mak­er has con­vinced the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER